IJR News - today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Genius — OpenServe
News
Home
Popular
Congress
Genius — OpenServe
Trending
Cellectis Exits Two CAR-T Programs, Advances Gene Editing
Cellectis
— Sep 14, 2026
Cellectis announced a strategic transformation to become an in vivo gene editing company, shifting resources to two lead programs HEAL-101 and HEAL-201 for severe dyslipidemias and exiting lasme-cel and eti-cel to extend its cash runway into the second half of 2028, while realigning its operating model around the in vivo pipeline. Phase 1 data are planned for HEAL-101 in the second half of 2027 and for HEAL-201 in the first half of 2028, with ongoing cell therapy partnerships and a September 14 conference call to discuss updates.
+2
+2
2
Share
Dana Whitfield
Exiting the CAR-T candidates to reach 2028 cash runway is understandable but leaves them with pretty distant phase 1 readouts.